3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
3
Lymphoid
3
Plasma cell
2
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
41
Myelodysplastic Syndromes
37
Leukemia
36
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Leukemia, Myeloid, Acute
31
Leukemia, Myelomonocytic, Chronic
28
Leukemia, Myeloid, Chronic-Phase
27
Leukemia, Lymphocytic, Chronic, B-Cell
25
Anemia, Refractory
25
Lymphoma, Non-Hodgkin
23
Lymphoma, Mantle-Cell
22
Leukemia, Myeloid, Accelerated Phase
22
Multiple Myeloma
21
Lymphoma, Follicular
21
Myeloproliferative Disorders
20
Congenital Abnormalities
20
Burkitt Lymphoma
20
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, B-Cell, Marginal Zone
19
Lymphoma
19
Lymphoma, Large-Cell, Immunoblastic
18
Hodgkin Disease
17
Primary Myelofibrosis
16
Blast Crisis
16
Dendritic Cell Sarcoma, Interdigitating
14
Neoplasms, Plasma Cell
11
Myelodysplastic-Myeloproliferative Diseases
11
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
11
Graft vs Host Disease
11
Recurrence
9
Interventions
Cyclophosphamide
4
fludarabine phosphate
2
fludarabine
2
Stem Cell Transplantation
2
Platelet Transfusion
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Bone Marrow Transplantation
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
cedazuridine
1
Thiotepa
1
Tacrolimus
1
Sertraline
1
Rituximab
1
Observation
1
Methotrexate
1
Cyclosporine
1
Cholecalciferol
1
Brentuximab Vedotin
1
Biopsy
1
Azacitidine
1
Aspirin
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Cyclosporine
×
Classical hematology
×
Clear all
NCT00636909
2017-04-06
MINI HEME
Beth Israel Deaconess Medical Center
Phase 2
Completed
25 enrolled